Successfully enrolled first-line metastatic pancreatic and third-line metastatic colorectal safety run-ins
Company moving to full enrollment pending independent safety review
Multi-center trial being conducted in collaboration with Roche and AIO builds on prior promising data from pancreatic and colorectal cancer trials
https://finance.yahoo.com/news/oncolytics-biotech-provides-enrollment-multi-130500259.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.